Download PDF
Semin Neurol 2001; 21(4): 407-416
DOI: 10.1055/s-2001-19412
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Pearls and Pitfalls in the Approach to Patients with Neurotoxic Syndromes

Daniel E. Rusyniak
  • Division of Medical Toxicology, Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, Indiana
Further Information

Publication History

Publication Date:
02 January 2002 (online)

    Permissions and Reprints

ABSTRACT

Neurotoxins are an important cause of neurologic disorders. A vast number of potentially neurotoxic compounds exist, including prescription drugs, illicit substances, and exposures through the workplace, residence, hobbies, and the environment. Effects of neurotoxins can mimic neurologic illnesses; therefore, it is important to consider neurotoxins in the differential diagnosis of any patient with neurological dysfunction. Paramount to the diagnosis of a possible neurotoxic syndrome is establishing causation. This can be done by a systematic approach utilizing principles in epidemiology and applying them to the individual patient. This approach is discussed in the following article in an attempt to bring structure to solving problems in a complex area of medicine.

KEYWORD

Neurotoxins - neurotoxicology - clinical approach - epidemiology

REFERENCES

  • 1 US Congress. Neurotoxicity: Identifying and Controlling Poisons of the Nervous System Washington, DC: Office of Technology Assessment 1990: 3
  • 2 Schaumburg H H. Human neurotoxic disease. In: Spencer PS, Schaumburg HH, eds. Experimental and Clinical Neurotoxicology New York: Oxford University Press 2000: 55
    Google Scholar
  • 3 Hill A B. The environment and disease: association or causation?.  Proc R Soc Med . 1965;  58 295-300
    PubMedGoogle Scholar
  • 4 Moeschlin S. Thallium poisoning.  Clin Toxicol . 1980;  17 133-146
    CrossrefPubMedGoogle Scholar
  • 5 Tromme I, Van Neste D, Dobbelaere F. Skin signs in the diagnosis of thallium poisoning [published erratum appears in Br J Dermatol 1998;139:170].  Br J Dermatol . 1998;  138 321-325
    CrossrefPubMedGoogle Scholar
  • 6 Bank W J, Pleasure D E, Suzuki K, Nigro M, Katz R. Thallium poisoning.  Arch Neurol . 1972;  26 456-464
    PubMedGoogle Scholar
  • 7 Moore D, House I, Dixon A. Thallium poisoning: diagnosis may be elusive but alopecia is the clue [published erratum appears in BMJ 1993;306:1603].  BMJ . 1993;  306 1527-1529
    PubMedGoogle Scholar
  • 8 Meggs W J, Hoffman R S, Shih R D, Weisman R S, Goldfrank L R. Thallium poisoning from maliciously contaminated food.  J Toxicol Clin Toxicol . 1994;  32 723-770
    PubMedGoogle Scholar
  • 9 Douglas K T, Bunni M A, Baindur S R. Thallium in biochemistry.  Int J Biochem . 1990;  22 429-438
    CrossrefPubMedGoogle Scholar
  • 10 Gehring P J, Hammond P B. The interrelationship between thallium and potassium in animals.  J Pharmacol Exp Ther . 1967;  155 187-201
    PubMedGoogle Scholar
  • 11 Mulkey J P, Oehme F W. A review of thallium toxicity [published erratum appears in Vet Hum Toxicol 1993;35:511].  Vet Hum Toxicol . 1993;  35 445-453
    PubMedGoogle Scholar
  • 12 Choi I S. Delayed neurologic sequelae in carbon monoxide intoxication.  Arch Neurol . 1983;  40 433-435
    CrossrefPubMedGoogle Scholar
  • 13 Min S K. A brain syndrome associated with delayed neuropsychiatric sequelae following acute carbon monoxide intoxication.  Acta Psychiatr Scand . 1986;  73 80-86
    CrossrefPubMedGoogle Scholar
  • 14 Klawans H L, Stein R W, Tanner C M, Goetz C G. A pure parkinsonian syndrome following acute carbon monoxide intoxication.  Arch Neurol . 1982;  39 302-304
    PubMedGoogle Scholar
  • 15 Zagami A S, Lethlean A K, Mellick R. Delayed neurological deterioration following carbon monoxide poisoning: MRI findings.  J Neurol . 1993;  240 113-116
    PubMedGoogle Scholar
  • 16 Song S Y, Okeda R, Funata N, Higashino F. An experimental study of the pathogenesis of the selective lesion of the globus pallidus in acute carbon monoxide poisoning in cats.  Acta Neuropathol (Berl) . 1983;  61 232-238
    CrossrefPubMedGoogle Scholar
  • 17 Okeda R, Funata N, Takano T. The pathogenesis of carbon monoxide encephalopathy in the acute phase: physiological and morphological correlation.  Acta Neuropathol (Berl) . 1981;  54 1-10
    CrossrefPubMedGoogle Scholar
  • 18 Thom S R. Leukocytes in carbon monoxide: mediated brain oxidative injury.  Toxicol Appl Pharmacol . 1993;  123 234-247
    CrossrefPubMedGoogle Scholar
  • 19 Raub J A, Mathieu-Nolf M, Hampson N B, Thom S R. Carbon monoxide poisoning: a public health perspective.  Toxicology . 2000;  145 1-14
    CrossrefPubMedGoogle Scholar
  • 20 Hormes J T, Filley C M, Rosenberg N L. Neurologic sequelae of chronic solvent vapor abuse.  Neurology . 1986;  36 698-702
    PubMedGoogle Scholar
  • 21 Rosenberg N L, Kleinschmidt-DeMasters B K, Davis K A, Dreisbach J N, Hormes J T, Filley C M. Toluene abuse causes diffuse central nervous system white matter changes.  Ann Neurol . 1988;  23 611-614
    CrossrefPubMedGoogle Scholar
  • 22 Keane J R. Toluene optic neuropathy.  Ann Neurol . 1978;  4 390
    CrossrefPubMedGoogle Scholar
  • 23 Ehyai A, Freemon F R. Progressive optic neuropathy and sensorineural hearing loss due to chronic glue sniffing.  J Neurol Neurosurg Psychiatry . 1983;  46 349-351
    PubMedGoogle Scholar
  • 24 Streicher H Z, Gabow P A, Moss A H, Kono D, Kaehny W D. Syndromes of toluene sniffing in adults.  Ann Intern Med . 1981;  94 758-762
    PubMedGoogle Scholar
  • 25 Yamanouchi N, Okada S, Kodama K. White matter changes caused by chronic solvent abuse.  AJNR . 1995;  16 1643-1649
    PubMedGoogle Scholar
  • 26 Schaumburg H H. Toluene. In: Spencer PS, Schaumburg HH, eds. Experimental and Clinical Neurotoxicology New York: Oxford University Press 2000: 1186
    Google Scholar
  • 27 Wiedmann K D, Power K G, Wilson J T, Hadley D M. Recovery from chronic solvent abuse.  J Neurol Neurosurg Psychiatry . 1987;  50 1712-1713
    PubMedGoogle Scholar
  • 28 Pryor G T. A toluene-induced motor syndrome in rats resembling that seen in some human solvent abusers.  Neurotoxicol Teratol . 1991;  13 387-400
    CrossrefPubMedGoogle Scholar
  • 29 Rusyniak D E. Case presentation: 67-year-old man with the diagnosis of Creutzfeldt-Jacob disease: something doesn't smell right.  Internet J Med Toxicol . 2001;  4 6-8
    PubMedGoogle Scholar
  • 30 Burns R, Thomas D W, Barron V J. Reversible encephalopathy possibly associated with bismuth subgallate ingestion.  Br Med J . 1974;  1 220-223
    PubMedGoogle Scholar
  • 31 Lowe D J. Adverse effects of bismuth subgallate: a further report from the Australian Drug Evaluation Committee.  Med J Aust . 1974;  2 664-666
    PubMedGoogle Scholar
  • 32 Supino-Viterbo V, Sicard C, Risvegliato M, Rancurel G, Buge A. Toxic encephalopathy due to ingestion of bismuth salts: clinical and EEG studies of 45 patients.  J Neurol Neurosurg Psychiatry . 1977;  40 748-752
    PubMedGoogle Scholar
  • 33 Ross J F, Sahenk Z, Hyser C, Mendell J R, Alden C L. Characterization of a murine model for human bismuth encephalopathy.  Neurotoxicology . 1988;  9 581-586
    PubMedGoogle Scholar
  • 34 Martin W R, Sloan J W, Wala E. Precipitated abstinence in orally dosed benzodiazepine-dependent dogs.  J Pharmacol Exp Ther . 1990;  255 744-755
    PubMedGoogle Scholar
  • 35 Sloan J W, Martin W R, Wala E P. Dependence-producing properties of alprazolam in the dog.  Pharmacol Biochem Behav . 1990;  35 651-657
    CrossrefPubMedGoogle Scholar
  • 36 Noyes R, Perry P J, Crowe R R. Seizures following the withdrawal of alprazolam.  J Nerv Ment Dis . 1986;  174 50-52
    PubMedGoogle Scholar
  • 37 Breier A, Charney D S, Nelson J C. Seizures induced by abrupt discontinuation of alprazolam.  Am J Psychiatry . 1984;  141 1606-1607
    PubMedGoogle Scholar